The MedTwenty Brief: Week 44, 2026
This week's three stories are all procurement notices, but they sit at different points in the NHS commercial cycle and at very different scales. Taken together, they suggest that framework agreements remain central to how the NHS buys, and that suppliers and investors still have to read carefully f

This week's three stories are all procurement notices, but they sit at different points in the NHS commercial cycle and at very different scales. Taken together, they suggest that framework agreements remain central to how the NHS buys, and that suppliers and investors still have to read carefully for what the notices leave out.
Supply Chain Coordination Limited's tender for pulse oximetry, capnography and related monitoring technologies looks furthest ahead. The framework is estimated at £250m excluding VAT, with £240m of that in Lot 1b for consumables. Finance carries a 40% weighting in both lots, which suggests price competitiveness will matter greatly, while the listed requirements on certification, sustainability and cyber security could shape who is able to bid. Bids are due on 30 November 2026 and an award decision is expected by 13 September 2027. The values are estimates of possible spend, not guaranteed spend.
At the other end of the scale, West Suffolk NHS Foundation Trust has awarded a works contract valued at £837.6m to Dragados SA for the new West Suffolk Hospital. The contract is recorded as a call-off from a framework agreement and runs to 1 December 2034. Yet the notice does not name the framework, say whether the figure is an estimate or includes VAT, or give a funding source or opening date. Contractors and investors tracking NHS capital activity may find it a useful reference, but the figure should be treated with caution. Leeds Teaching Hospitals NHS Trust's award to Exact Sciences UK, Ltd. for the Oncotype DX breast recurrence score test is far smaller, at £337,500 within a stated range up to £405,000. It is also a framework call-off, and the trust states that the test is uniquely available from the current supplier. That could point to steady, contract-based demand where the trust sees no alternative.
The common thread is that value and route to market are visible, but the detail behind them is often incomplete. Worth watching are the 2026 deadlines in the monitoring tender, and whether future notices name their frameworks and clarify VAT and value ranges, which would make comparisons easier for buyers, suppliers and investors.
A shorter week: three developments that matter
In this week's Brief
- 1Supply Chain Coordination tenders £250m pulse oximetry and capnography framework
A tender update values the framework for pulse oximetry, capnography and related monitoring technologies at an estimated £250m excluding VAT. Bids are due on 30 November 2026.
- 2West Suffolk NHS trust awards £837.6m new hospital works contract to Dragados
West Suffolk NHS Foundation Trust has awarded a works contract valued at £837.6m to Dragados SA for the design and construction of a new West Suffolk Hospital, according to a Contracts Finder notice.
- 3Leeds Teaching Hospitals awards £337,500 Oncotype DX test contract to Exact Sciences UK
A Contracts Finder notice records a two-year award for the Oncotype DX breast recurrence score test, called off from a framework agreement. The notice gives a value range of £337,500 to £405,000.
Related stories

NHS & Healthcare Finance
NHS England directly awards PERFORMS £1.4m for breast and lung screening training

Regulation & Policy
MHRA publishes 2026–2030 plan to widen patient involvement in regulation

Regulation & Policy
MHRA grants conditional approval to triheptanoin for rare inherited fatty acid disorders